---
layout: default
title: Bevacizumab
parent: 僅模型預測 (L5)
nav_order: 18
evidence_level: L5
indication_count: 10
---

# Bevacizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Bevacizumab (DB00112): Evidence Pack Incomplete — Repurposing Analysis Unavailable

## One-Sentence Summary

Bevacizumab (DrugBank: DB00112) is an antineoplastic biologic agent whose original approved indications and mechanism of action are not captured in the current Evidence Pack.
The TxGNN model has **not yet generated any predicted indications** for this compound, meaning the repurposing analysis pipeline has not completed.
This report documents the current data state and outlines the information required before a full evaluation can proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in current Evidence Pack |
| Predicted New Indication | None — TxGNN prediction output is absent |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction not yet completed) |
| Market Status | Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** — critical data gaps must be resolved first |

---

## Why Is This Prediction Reasonable?

This section cannot be completed because the `predicted_indications` array in the Evidence Pack is empty. No TxGNN prediction output has been received for Bevacizumab (DB00112), so there is no predicted indication to evaluate for mechanistic plausibility.

Additionally, the mechanism of action (MOA) field is currently unavailable (Data Gap DG002). Without MOA data, even a manual bridging analysis between the original and any candidate new indication is not possible.

Once the TxGNN pipeline generates predictions and the MOA is retrieved from DrugBank, this section will describe the anti-VEGF pathway and its applicability to the candidate indication.

---

## Clinical Trial Evidence

Currently no related clinical trials are associated with a TxGNN-predicted repurposing indication, because no prediction has been generated.

---

## Literature Evidence

Currently no related literature is available for a TxGNN-predicted repurposing indication, because no prediction has been generated.

---

## Market Information

| Item | Status |
|------|--------|
| Market Status | Not marketed (未上市) |
| Total Authorizations | 0 |
| Licenses on Record | None |

No authorization records are available. The regulatory query returned zero results.

---

## Cytotoxicity

Bevacizumab (DB00112) is an antineoplastic biologic agent (anti-VEGF monoclonal antibody). Although the DrugBank category fields are not present in this Evidence Pack, the drug is known to belong to the targeted therapy class.

| Item | Content |
|------|---------|
| Cytotoxicity Classification | Targeted therapy — anti-VEGF monoclonal antibody (not conventional cytotoxic) |
| Myelosuppression Risk | Low (mechanism does not directly target haematopoietic cells; thrombocytopenia is not a primary toxicity) |
| Emetogenicity Classification | Minimal to low |
| Monitoring Items | Blood pressure (hypertension is a class effect), CBC, urine protein, wound healing status, thromboembolic event surveillance |
| Handling Protection | Standard biologic handling; not classified as conventional cytotoxic — no closed-system drug transfer device required, but follow institutional biologic handling SOPs |

> **Note:** Full cytotoxicity characterisation should reference the package insert. The warnings and contraindications fields (Data Gap DG001) are currently absent from this Evidence Pack.

---

## Safety Considerations

All key warnings and contraindication fields returned no data in the current Evidence Pack. No drug–drug interaction records were found (DDI query status: not found).

> Please refer to the package insert for complete safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for Bevacizumab (DB00112) is critically incomplete: the TxGNN model has produced no predicted indications, both the mechanism of action and the regulatory safety data are absent, and the drug has zero authorization records in the target market. There is no evidence base on which to build a repurposing recommendation at this time.

**To proceed, the following is needed:**

- **[DG001 — Blocking]** Retrieve package insert (仿單) from the regulatory authority website; extract warnings, contraindications, and approved indication text
- **[DG002 — High]** Query DrugBank API for DB00112 to populate MOA, drug categories, and toxicity data
- **Re-run TxGNN pipeline** — confirm that Bevacizumab is included in the prediction run and that `predicted_indications` output is correctly written to the Evidence Pack
- **Verify market scope** — confirm whether the target regulatory jurisdiction for this candidate is Taiwan (TFDA) or Germany (BfArM), as the Evidence Pack field names and the Chinese-language status text are currently inconsistent
- **DDI retrieval** — retry DDI database query once the drug profile is more completely populated
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

